Coupang Inc vs Charles River Laboratories Intl. Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B). The key difference: Coupang Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Charles River Laboratories Intl. Inc for 33 Days on average.
| CPNG | CRL | |
|---|---|---|
Market Cap | $27.70B | $14.23B |
Volume | 27,703,608 | 1,176,885 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $310.77 |
52-Week Low | $13.75 | $149.93 |
Typical Hold Time | 55 Days | 33 Days |
Enterprise Value | $27.22B | $17.06B |
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.82, up 6.82% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with positive moving averages and institutional support. Revenue growth remains robust at $34.53 billion for 2025, though profitability metrics show challenges with negative net income margin and ROE. Analyst consensus is strongly bullish with 87.5% buy ratings and a $25.25 price target, representing significant upside potential from current levels.
The investment case hinges on Coupang's dominant South Korean market position and expanding logistics network, but faces headwinds from inconsistent profitability and competitive pressures. While valuation appears reasonable on sales (P/S 0.8), high P/E ratio reflects earnings volatility. Key risks include execution challenges in international expansion and margin pressure from logistics investments. The stock offers growth exposure but requires careful monitoring of profitability trends.
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →